Human airway and peripheral blood eosinophils enhance Th1 and Th2 cytokine secretion

Liu, L.-Y.; Mathur, Sameer K.; Sedgwick, Julie B.; Jarjour, Nizar N.; Busse, William W.; Kelly, Elizabeth A.

doi:10.1111/j.1398-9995.2006.01060.x

Cited by 55 publications

(67 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We show that abatacept treatment significantly reduced the levels of these cytokines that are indicators of systemic inflammation, which regulates T cell responses and the proinflammatory response of eosinophils (35,36). Pathology induced by SEB is dependent upon T cell and eosinophil activation, and subsequently will lead to a systemic inflammatory response (37). We also observed that SEBdependent IL-2 expression in human and murine cell cultures was prevented by abatacept.…”

Section: Discussionsupporting

confidence: 52%

Interference of the T Cell and Antigen-Presenting Cell Costimulatory Pathway Using CTLA4-Ig (Abatacept) Prevents Staphylococcal Enterotoxin B Pathology

Whitfield

Taylor

Risdall

et al. 2017

The Journal of Immunology

View full text Add to dashboard Cite

Staphylococcal enterotoxin B (SEB) is a bacterial superantigen that binds the receptors in the APC/T cell synapse and causes increased proliferation of T cells and a cytokine storm syndrome in vivo. Exposure to the toxin can be lethal and cause significant pathology in humans. The lack of effective therapies for SEB exposure remains an area of concern, particularly in scenarios of acute mass casualties. We hypothesized that blockade of the T cell costimulatory signal by the CTLA4-Ig synthetic protein (abatacept) could prevent SEB-dependent pathology. In this article, we demonstrate mice treated with a single dose of abatacept 8 h post SEB exposure had reduced pathology compared with control SEB-exposed mice. SEB-exposed mice showed significant reductions in body weight between days 4 and 9, whereas mice exposed to SEB and also treated with abatacept showed no weight loss for the duration of the study, suggesting therapeutic mitigation of SEB-induced morbidity. Histopathology and magnetic resonance imaging demonstrated that SEB mediated lung damage and edema, which were absent after treatment with abatacept. Analysis of plasma and lung tissues from SEB-exposed mice treated with abatacept demonstrated significantly lower levels of IL-6 and IFN-γ (p < 0.0001), which is likely to have resulted in less pathology. In addition, exposure of human and mouse PBMCs to SEB in vitro showed a significant reduction in levels of IL-2 (p < 0.0001) after treatment with abatacept, indicating that T cell proliferation is the main target for intervention. Our findings demonstrate that abatacept is a robust and potentially credible drug to prevent toxic effects from SEB exposure.

show abstract

Section: Discussionsupporting

confidence: 52%

Interference of the T Cell and Antigen-Presenting Cell Costimulatory Pathway Using CTLA4-Ig (Abatacept) Prevents Staphylococcal Enterotoxin B Pathology

Whitfield

Taylor

Risdall

et al. 2017

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…The observed low concentrations of IL-4, IL-5 and IL-13 as well as the higher expression of IFN-γ in our elderly patients with AD and low total IgE were comparable to nonatopic or intrinsic AD patients [25]. Our data suggest that patients with AD and low total IgE are not sensitized to typical protein allergens that induce Th2 responses, instead, they are sensitized to staphylococcal superantigens that induce Th1 responses.…”

Section: Discussionmentioning

confidence: 77%

Clinical Features and Immunological Markers of Atopic Dermatitis in Elderly Patients

Bożek¹,

Fisher²,

Filipowska³

et al. 2011

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is increasing among the elderly. Staphylococcus aureus colonization is one of the most important aggravating factors in AD. Objective: This study analyses the clinical features of AD in elderly patients and determines the pathogenic roles of staphylococcal superantigens in AD with low and high total IgE levels. Methods:S. aureus enterotoxin genes were evaluated using PCR. Additionally, S. aureus-specific IgE levels and peripheral blood lymphocyte profiles were assessed. Results: A total of 44 women and 77 men diagnosed with AD with a mean age of 68.92 ± 6.51 years were evaluated. In 17 (68%) patients with AD and low levels of total IgE, there was a positive correlation between the positive results for enterotoxin B, S. aureus-specific IgE antibodies and Th1 cytokine profiles (Spearman’s rank correlation test, r = 0.89, p < 0.05). Conclusion: Our results indicate that AD patients with low total IgE levels differ in immunopathogenesis from AD patients with high circulating levels of total IgE AD.

show abstract

“…Besides the already established immediate hypersensitivity upon participation of IgE antibodies, mast cells/basophils, eosinophils and Th 2 lymphocytes, other hypersensitivity mechanisms can also be involved in this condition [1,2,3,4,5,6,7,8,9,10,11]. However, our knowledge of the role of the other mechanisms in this disorder is still relatively limited [1,2,3,6,11,12,13,14].…”

Section: Introductionmentioning

confidence: 99%

Delayed Type of Asthmatic Response to Allergen Challenge and Cytokines in the Peripheral Blood

Pelikán¹

2012

Respiration

View full text Add to dashboard Cite

Background: Patients with allergic bronchial asthma can develop various types of asthmatic response to bronchial challenge with allergens, such as immediate (IAR), late (LAR) or delayed (DYAR) response, due to different immunological mechanisms. Objective: The DYAR, beginning within 26– 32 h after the challenge, reaching its maximum between 32 and 48 h and resolving within 56 h (p < 0.001), differs from IAR and LAR regarding the clinical features, diagnostic and immunological parameters. Methods: The repeated DYAR (p < 0.001) in 28 patients was supplemented with recording of cytokine concentrations in the serum before and up to 72 h after the bronchial challenge by means of enzyme-linked immunoassay. Results: The DYAR was accompanied by a significant increase in the serum concentration (p < 0.05) of IL-2 at 24, 36 and 48 h; IL-10 at 12, 24, 36 and 48 h; IL-18 at 12 and 24 h; IFN-γ at 24, 36, 48 and 56 h; G-CSF at 1 and 12 h; TNF-α at 12, 36 and 48 h and TGF-β at 12 and 36 h, and a significant decrease in the concentration (p < 0.05) of IL-7 at 36 and 48 h and IL-12p70 at 12 h, as compared both with the prechallenge and with PBS control values. No significant changes in the serum cytokines were recorded during the PBS controls (p > 0.2). Conclusions: These results support the evidence for an active involvement of the Th₁ cells, neutrophils, monocytes, macrophages, epithelial cells and endothelial cells, upon cooperation of other cell types, in the immunological mechanism(s) underlying the DYAR.

show abstract

Human airway and peripheral blood eosinophils enhance Th1 and Th2 cytokine secretion

Cited by 55 publications

References 35 publications

Interference of the T Cell and Antigen-Presenting Cell Costimulatory Pathway Using CTLA4-Ig (Abatacept) Prevents Staphylococcal Enterotoxin B Pathology

Interference of the T Cell and Antigen-Presenting Cell Costimulatory Pathway Using CTLA4-Ig (Abatacept) Prevents Staphylococcal Enterotoxin B Pathology

Clinical Features and Immunological Markers of Atopic Dermatitis in Elderly Patients

Delayed Type of Asthmatic Response to Allergen Challenge and Cytokines in the Peripheral Blood

Contact Info

Product

Resources

About